TransCode Therapeutics Announces Updated Phase 1a Data for TTX‑MC138

What Happened

• On September 28, 2026 TransCode Therapeutics, Inc. filed a Form 8‑K (Item 8.01) to announce updated clinical data from its Phase 1a dose clinical trial of investigational candidate TTX‑MC138. The company issued a press release with the data, which is attached to the filing as Exhibit 99.1.

Key Details

• Event filed: Form 8‑K, Item 8.01 (Other Events) on September 28, 2026.
• Program: TTX‑MC138 — results reported from the Phase 1a dose clinical trial.
• Disclosure: Updated clinical data were announced via a press release incorporated as Exhibit 99.1 to the 8‑K.
• No financial results or executive changes were reported in this filing.

Why It Matters

• Clinical data updates are material for biotech investors because they provide new information about a drug candidate’s safety, tolerability, or early activity and can affect development plans, timelines, and valuation.
• Investors should review the attached press release (Exhibit 99.1) for the specific data and any statements on next steps or timing. Monitor subsequent company filings and announcements for detailed results, regulatory guidance, or trial progress.